Shares of SenesTech Inc (NASDAQ:SNES) have earned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.
Analysts have set a one year consensus price objective of $2.50 for the company, according to Zacks. Zacks has also given SenesTech an industry rank of 69 out of 256 based on the ratings given to its competitors.
Separately, ValuEngine upgraded SenesTech from a “hold” rating to a “buy” rating in a research note on Friday, June 28th.
SenesTech (NASDAQ:SNES) last released its earnings results on Wednesday, May 15th. The company reported ($0.10) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.10). The firm had revenue of $0.02 million during the quarter. SenesTech had a negative return on equity of 186.65% and a negative net margin of 3,908.08%. Sell-side analysts anticipate that SenesTech will post -0.19 earnings per share for the current fiscal year.
In other news, CEO Kenneth S. Siegel purchased 696,296 shares of the company’s stock in a transaction on Tuesday, July 16th. The stock was bought at an average cost of $1.35 per share, for a total transaction of $939,999.60. Following the completion of the purchase, the chief executive officer now directly owns 702,558 shares of the company’s stock, valued at approximately $948,453.30. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 10.91% of the company’s stock.
An institutional investor recently raised its position in SenesTech stock. Virtu Financial LLC grew its position in shares of SenesTech Inc (NASDAQ:SNES) by 87.4% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 56,447 shares of the company’s stock after acquiring an additional 26,322 shares during the quarter. Virtu Financial LLC owned about 0.24% of SenesTech worth $69,000 at the end of the most recent quarter. 6.78% of the stock is currently owned by hedge funds and other institutional investors.
SenesTech Company Profile
SenesTech, Inc develops a technology for managing animal pest populations through fertility control. The company focuses on commercializing ContraPest, a fertility control product for use in controlling rat populations. It is also developing a pipeline of fertility control and animal health products, including feral animal fertility control, non-surgical spay and neutering, boar taint, and animal cancer treatment.
See Also: What is a death cross?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with MarketBeat.com's FREE daily email newsletter.